- Home
- SNGX vs STRR Comparison
SNGX vs STRR Comparison
Compare SNGX & STRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- STRR
- Stock Information
- Founded
- SNGX 1987
- STRR 1985
- Country
- SNGX United States
- STRR United States
- Employees
- SNGX N/A
- STRR N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- STRR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- SNGX Health Care
- STRR Health Care
- Exchange
- SNGX Nasdaq
- STRR Nasdaq
- Market Cap
- SNGX 6.5M
- STRR 6.3M
- IPO Year
- SNGX 1987
- STRR N/A
- Fundamental
- Price
- SNGX $1.28
- STRR $1.95
- Analyst Decision
- SNGX
- STRR Strong Buy
- Analyst Count
- SNGX 0
- STRR 1
- Target Price
- SNGX N/A
- STRR $5.00
- AVG Volume (30 Days)
- SNGX 2.7M
- STRR 9.6K
- Earning Date
- SNGX 08-08-2025
- STRR 08-12-2025
- Dividend Yield
- SNGX N/A
- STRR N/A
- EPS Growth
- SNGX N/A
- STRR N/A
- EPS
- SNGX N/A
- STRR N/A
- Revenue
- SNGX $2,342.00
- STRR $57,165,000.00
- Revenue This Year
- SNGX N/A
- STRR $33.64
- Revenue Next Year
- SNGX N/A
- STRR $22.87
- P/E Ratio
- SNGX N/A
- STRR N/A
- Revenue Growth
- SNGX N/A
- STRR 34.33
- 52 Week Low
- SNGX $1.09
- STRR $1.72
- 52 Week High
- SNGX $8.55
- STRR $5.35
- Technical
- Relative Strength Index (RSI)
- SNGX 34.55
- STRR 43.68
- Support Level
- SNGX $1.09
- STRR $1.94
- Resistance Level
- SNGX $1.88
- STRR $2.00
- Average True Range (ATR)
- SNGX 0.14
- STRR 0.05
- MACD
- SNGX -0.01
- STRR 0.00
- Stochastic Oscillator
- SNGX 22.78
- STRR 16.67
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About STRR Star Equity Holdings Inc.
Star Equity Holdings Inc is a multi-industry diversified holding company. It operates in two segments: Building Solutions segment, through KBS, EBGL and TT, it services residential and commercial construction projects by manufacturing modular housing units, structural wall panels, permanent wood foundation systems, other engineered wood products, and supply general contractors with building materials; and Investments segment, which holds corporate-owned real estate, currently includes one manufacturing facility and the equipment for another manufacturing facility in Maine that it leases back to KBS and its manufacturing facility in Wisconsin that it leases back to TT. The company derives maximum revenue from Building Solutions Segment.